Figure 6.

Treating physicians preferentially implemented top ranked therapy options listed on VMTB reports. (A) Distribution of the highest ranked therapy option chosen by each patient and their treating oncologist (1 per patient, lesser ranked implementations omitted). (B) Distribution of therapy option rankings implemented that included an immune checkpoint inhibitor (PD-1/PD-L1/CTLA-4/OX40 antibody). It is important to note that immunotherapy was nearly universally recommended (with or without molecular support) but primarily in the context of a clinical trial and rarely as an off-label option.